The US Supreme Court’s Mayo and Myriad decisions have brought challenges to subject matter eligibility to the forefront in the biomedical industry, but they do not signal the end of biomedical patents. Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.
The US and China take very different approaches to the patentability of a range of inventions in the life sciences field, as Yu Guo of China Patent Agent reports.
Inter-partes reviews (IPRs) can be a powerful weapon against patents listed in the Orange Book. However, IPR practice favours a petitioner who has carefully thought about the issues and crafted the best strategy, says Mark Remus of Brinks Gilson & Lione.
The Brazilian Federal Prosecutor’s Office has taken court action against Roche for allegedly abusing IP rights in its sales of Herceptin to state governments. Anderson Ribeiro and Ricardo Campello of Provedel Advogados analyse the case.
Despite the clamour for more guidance on the scope and application of the Mayo test on patent eligibility, the US Supreme Court denied Sequenom’s petition in its dispute with Ariosa, as Stephen Stout and Rachael McClure of Vinson & Elkins explain.
Everyone benefits from an efficiently run clinical drug study, including sponsors, contract research organisations, the investigator sites where patients are treated and observed, and most of all, patients, says Charlie Nicholson of Premier Research.
The Canadian Intellectual Property Office has updated its guidelines on procedural and examination practices, with some changes affecting biotechnology and medicinal inventions, explain Jason Markwell and Stephanie Anderson of Belmore Neidrauer.
IP and innovation in Mexico has come a long way, and the country’s part in international trade treaties will provide further great opportunities, says Nuria Becerril of Becerril, Coca & Becerril.
The system governing access to genetic resources in Brazil has been strengthened by a recent legal update, explain Andrea Granthon and Tatiana Schuenck of Luiz Leonardos & Advogados.
Aided by strong patent protection, efforts are continuing in Brazil to develop a vaccine against the notorious dengue fever. Gabriel Di Blasi of Di Blasi, Parente & Associados and Jorge Kalil of the Instituto Butantan explain more.